WO2017144973A3 - Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pds5 - Google Patents

Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pds5 Download PDF

Info

Publication number
WO2017144973A3
WO2017144973A3 PCT/IB2017/000242 IB2017000242W WO2017144973A3 WO 2017144973 A3 WO2017144973 A3 WO 2017144973A3 IB 2017000242 W IB2017000242 W IB 2017000242W WO 2017144973 A3 WO2017144973 A3 WO 2017144973A3
Authority
WO
WIPO (PCT)
Prior art keywords
pds5
inhibitor
pharmaceutical formulations
novel pharmaceutical
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2017/000242
Other languages
English (en)
French (fr)
Other versions
WO2017144973A2 (es
Inventor
Vinaykumar LAD
Keyur Patel
Chetan Doshi
Barry Sherman
Original Assignee
Apotex Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59684801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2017144973(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotex Technologies Inc. filed Critical Apotex Technologies Inc.
Publication of WO2017144973A2 publication Critical patent/WO2017144973A2/es
Publication of WO2017144973A3 publication Critical patent/WO2017144973A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para el tratamiento curativo o profiláctico de la disfunción sexual en mamíferos machos y hembras que comprende (6R-trans)-6-(1,3-benzodioxol-5-il)-2,3,6,7,12,12a-hexahidro-2-metil-pirazino [1',2' :1,6]pirido[3,4-b]indol-1,4-diona) o una sal o un solvato farmacéuticamente aceptables del mismo, junto con portadores farmacéuticamente aceptables.
PCT/IB2017/000242 2016-02-26 2017-02-17 Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pds5 WO2017144973A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016002581A MX2016002581A (es) 2016-02-26 2016-02-26 Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5.
MXMX/A/2016/002581 2016-02-26

Publications (2)

Publication Number Publication Date
WO2017144973A2 WO2017144973A2 (es) 2017-08-31
WO2017144973A3 true WO2017144973A3 (es) 2017-11-23

Family

ID=59684801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/000242 WO2017144973A2 (es) 2016-02-26 2017-02-17 Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pds5

Country Status (3)

Country Link
CL (1) CL2018002441A1 (es)
MX (1) MX2016002581A (es)
WO (1) WO2017144973A2 (es)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610668A1 (en) * 2005-08-29 2007-03-08 Teva Pharmaceutical Industries Ltd. Solid particulate tadalafil having a bimodal particle size distribution
WO2013109230A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising tadalafil
WO2014167579A2 (en) * 2013-03-28 2014-10-16 Astron Research Limited Stable pharmaceutical compositions of tadalafil

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610668A1 (en) * 2005-08-29 2007-03-08 Teva Pharmaceutical Industries Ltd. Solid particulate tadalafil having a bimodal particle size distribution
WO2013109230A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising tadalafil
WO2014167579A2 (en) * 2013-03-28 2014-10-16 Astron Research Limited Stable pharmaceutical compositions of tadalafil

Also Published As

Publication number Publication date
CL2018002441A1 (es) 2018-11-16
WO2017144973A2 (es) 2017-08-31
MX2016002581A (es) 2017-08-25

Similar Documents

Publication Publication Date Title
WO2018033853A3 (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
MX2019013643A (es) Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona.
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
MX2020002711A (es) Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
WO2013128028A8 (en) Pyrazolo-triazine derivatives as selective cyclin- dependent kinase inhibitors
IL241573B (en) Transformed histories of [2h]imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidine-4[5h]-one, a pharmaceutical preparation containing them and their use as drugs
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
WO2011156405A3 (en) Oral spray formulations and methods for administration of sildenafil
MX2022001966A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
EA201171243A1 (ru) Производное бензодиазепина для лечения гематопоэтических новообразований и лейкоза
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2021014674A (es) Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
EA201991877A2 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
PL3986561T3 (pl) Pochodne pirydo[2,3-d]pirymidyny jako inhibitory replikacji ludzkiego wirusa niedoboru odporności
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
WO2017144973A3 (es) Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pds5
MX2019000159A (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.
WO2014193881A8 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
WO2014027982A3 (en) Novel effervescent sachet formulations of dapoxetine and a pde5 inhibitor

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17755890

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17755890

Country of ref document: EP

Kind code of ref document: A2